Literature DB >> 1312270

DNA binding activity is required for EBNA 1-dependent transcriptional activation and DNA replication.

M Polvino-Bodnar1, P A Schaffer.   

Abstract

Epstein-Barr virus nuclear antigen 1 (EBNA 1) has been shown to be a sequence-specific DNA binding protein that is required for the replication of episomal elements carrying the viral origin of DNA replication, oriP, as well as for the activation of a specific transcriptional enhancer. We have constructed and analyzed a series of deletion and nonsense mutants in a cloned copy of the EBNA 1 gene and have tested mutant peptides for the ability (a) to bind to a synthetic oligonucleotide containing a consensus EBNA 1 binding site, (b) to activate the EBNA 1-specific enhancer, and (c) to drive replication of an oriP-bearing plasmid in a transient replication assay. The presence of a DNA binding domain in the carboxy-terminal third of the protein was confirmed. Interestingly, neither the acidic tail nor the Gly-Ala copolymer of EBNA 1 contributes significantly to binding. In addition to sequences in the carboxy-terminal portion of the protein, our data indicate that sequences in the amino-terminal portion of the polypeptide affect the binding of EBNA 1 to its target sequence. Further, we show that EBNA 1 binds to its recognition sequence as a dimer. Results of transient expression assays indicate that the ability of EBNA 1 species to activate the transcriptional enhancer and to drive the replication of oriP plasmids is directly dependent on the ability of the polypeptides to bind to the EBNA 1 consensus binding sequence.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312270     DOI: 10.1016/0042-6822(92)90461-w

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

1.  Functional analyses of the EBNA1 origin DNA binding protein of Epstein-Barr virus.

Authors:  D F Ceccarelli; L Frappier
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  The linking regions of EBNA1 are essential for its support of replication and transcription.

Authors:  D Mackey; B Sugden
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

3.  The Herpesvirus Saimiri open reading frame 73 gene product interacts with the cellular protein p32.

Authors:  Kersten T Hall; Mathew S Giles; Michael A Calderwood; Delyth J Goodwin; David A Matthews; Adrian Whitehouse
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

4.  Dominant-negative inhibitors of EBNA-1 of Epstein-Barr virus.

Authors:  A L Kirchmaier; B Sugden
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

5.  Identification of EBNA1 amino acid sequences required for the interaction of the functional elements of the Epstein-Barr virus latent origin of DNA replication.

Authors:  K Goldsmith; L Bendell; L Frappier
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

6.  Separation of the complex DNA binding domain of EBNA-1 into DNA recognition and dimerization subdomains of novel structure.

Authors:  M R Chen; J M Middeldorp; S D Hayward
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

7.  Multiple regions within EBNA1 can link DNAs.

Authors:  D Mackey; T Middleton; B Sugden
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

8.  DNA binding and modulation of gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus.

Authors:  A C Garber; M A Shu; J Hu; R Renne
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

9.  Thermodynamics of cooperative DNA recognition at a replication origin and transcription regulatory site.

Authors:  Mariano Dellarole; Ignacio E Sánchez; Gonzalo de Prat Gay
Journal:  Biochemistry       Date:  2010-11-10       Impact factor: 3.162

Review 10.  Targeting mitotic chromosomes: a conserved mechanism to ensure viral genome persistence.

Authors:  Katherine M Feeney; Joanna L Parish
Journal:  Proc Biol Sci       Date:  2009-01-20       Impact factor: 5.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.